Mediwound Ltd
NASDAQ:MDWD

Watchlist Manager
Mediwound Ltd Logo
Mediwound Ltd
NASDAQ:MDWD
Watchlist
Price: 16.91 USD -2.76% Market Closed
Market Cap: 182.5m USD
Have any thoughts about
Mediwound Ltd?
Write Note

Intrinsic Value

MDWD's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one MDWD stock under the Base Case scenario is 10.75 USD. Compared to the current market price of 16.91 USD, Mediwound Ltd is Overvalued by 36%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MDWD Intrinsic Value
10.75 USD
Overvaluation 36%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Mediwound Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MDWD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MDWD?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Mediwound Ltd

Provide an overview of the primary business activities
of Mediwound Ltd.

What unique competitive advantages
does Mediwound Ltd hold over its rivals?

What risks and challenges
does Mediwound Ltd face in the near future?

Summarize the latest earnings call
of Mediwound Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Mediwound Ltd.

Provide P/S
for Mediwound Ltd.

Provide P/E
for Mediwound Ltd.

Provide P/OCF
for Mediwound Ltd.

Provide P/FCFE
for Mediwound Ltd.

Provide P/B
for Mediwound Ltd.

Provide EV/S
for Mediwound Ltd.

Provide EV/GP
for Mediwound Ltd.

Provide EV/EBITDA
for Mediwound Ltd.

Provide EV/EBIT
for Mediwound Ltd.

Provide EV/OCF
for Mediwound Ltd.

Provide EV/FCFF
for Mediwound Ltd.

Provide EV/IC
for Mediwound Ltd.

Show me price targets
for Mediwound Ltd made by professional analysts.

What are the Revenue projections
for Mediwound Ltd?

How accurate were the past Revenue estimates
for Mediwound Ltd?

What are the Net Income projections
for Mediwound Ltd?

How accurate were the past Net Income estimates
for Mediwound Ltd?

What are the EPS projections
for Mediwound Ltd?

How accurate were the past EPS estimates
for Mediwound Ltd?

What are the EBIT projections
for Mediwound Ltd?

How accurate were the past EBIT estimates
for Mediwound Ltd?

Compare the revenue forecasts
for Mediwound Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Mediwound Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Mediwound Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Mediwound Ltd compared to its peers.

Compare the P/E ratios
of Mediwound Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Mediwound Ltd with its peers.

Analyze the financial leverage
of Mediwound Ltd compared to its main competitors.

Show all profitability ratios
for Mediwound Ltd.

Provide ROE
for Mediwound Ltd.

Provide ROA
for Mediwound Ltd.

Provide ROIC
for Mediwound Ltd.

Provide ROCE
for Mediwound Ltd.

Provide Gross Margin
for Mediwound Ltd.

Provide Operating Margin
for Mediwound Ltd.

Provide Net Margin
for Mediwound Ltd.

Provide FCF Margin
for Mediwound Ltd.

Show all solvency ratios
for Mediwound Ltd.

Provide D/E Ratio
for Mediwound Ltd.

Provide D/A Ratio
for Mediwound Ltd.

Provide Interest Coverage Ratio
for Mediwound Ltd.

Provide Altman Z-Score Ratio
for Mediwound Ltd.

Provide Quick Ratio
for Mediwound Ltd.

Provide Current Ratio
for Mediwound Ltd.

Provide Cash Ratio
for Mediwound Ltd.

What is the historical Revenue growth
over the last 5 years for Mediwound Ltd?

What is the historical Net Income growth
over the last 5 years for Mediwound Ltd?

What is the current Free Cash Flow
of Mediwound Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Mediwound Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Mediwound Ltd

Current Assets 37.3m
Cash & Short-Term Investments 29.2m
Receivables 4.9m
Other Current Assets 3.2m
Non-Current Assets 20m
PP&E 19.2m
Intangibles 132k
Other Non-Current Assets 691k
Current Liabilities 22.6m
Accounts Payable 2.7m
Other Current Liabilities 19.9m
Non-Current Liabilities 16.8m
Long-Term Debt 6.4m
Other Non-Current Liabilities 10.5m
Efficiency

Earnings Waterfall
Mediwound Ltd

Revenue
20.1m USD
Cost of Revenue
-17.5m USD
Gross Profit
2.7m USD
Operating Expenses
-17.8m USD
Operating Income
-15.1m USD
Other Expenses
-4.8m USD
Net Income
-20m USD

Free Cash Flow Analysis
Mediwound Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q2 2024, MediWound achieved significant milestones, including the completion of a new manufacturing facility for NexoBrid, expected to be operational in 2025. Revenue for the quarter was $5.1 million, driven by Vericel's increased orders. However, net loss grew to $6.3 million, largely due to financial expenses from warrant revaluation. EscharEx received €16.25 million in European funding for its diabetic foot ulcer indication expansion, setting the stage for future trials. Additionally, the company secured $25 million in funding from Mölnlycke Healthcare, bolstering its financial position and strategic collaborations .

What is Earnings Call?
Fundamental Scores

MDWD Profitability Score
Profitability Due Diligence

Mediwound Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Year Average ROIC
Exceptional Revenue Growth Forecast
Positive Gross Profit
52/100
Profitability
Score

Mediwound Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

MDWD Solvency Score
Solvency Due Diligence

Mediwound Ltd's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
54/100
Solvency
Score

Mediwound Ltd's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MDWD Price Targets Summary
Mediwound Ltd

Wall Street analysts forecast MDWD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MDWD is 30.35 USD with a low forecast of 25.25 USD and a high forecast of 37.8 USD.

Lowest
Price Target
25.25 USD
49% Upside
Average
Price Target
30.35 USD
79% Upside
Highest
Price Target
37.8 USD
124% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MDWD?

Click here to dive deeper.

Dividends

Mediwound Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for MDWD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Mediwound Ltd Logo
Mediwound Ltd

Country

Israel

Industry

Pharmaceuticals

Market Cap

182.5m USD

Dividend Yield

0%

Description

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Contact

YAVNE
42 Hayarkon Street
+972779714100.0
www.mediwound.com

IPO

2014-03-20

Employees

77

Officers

Chief Executive Officer
Mr. Ofer Gonen B.Sc.
Chief Financial Officer
Ms. Hani Luxenburg
Executive VP, General Counsel & Corporate Secretary
Mr. Yaron Meyer Adv.
Chief Research & Development Officer
Dr. Ety Klinger MBA, Ph.D.
Co-Founder
Dr. Lior Rosenberg M.D.
COO & Chief Commercial Officer
Dr. Shmulik Hess Ph.D.
Show More
Executive Director of Manufacturing Science & Technology
Dr. Liron Gal
Executive Vice President of Strategy & Corporate Development
Mr. Barry J. Wolfenson
Chief Medical Officer
Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc.
Show Less

See Also

Discover More
What is the Intrinsic Value of one MDWD stock?

The intrinsic value of one MDWD stock under the Base Case scenario is 10.75 USD.

Is MDWD stock undervalued or overvalued?

Compared to the current market price of 16.91 USD, Mediwound Ltd is Overvalued by 36%.

Back to Top